Literature DB >> 14719835

Iloprost for the treatment of bone marrow edema in the hindfoot.

N Aigner1, R Meizer, G Stolz, G Petje, C Krasny, F Landsiedl, G Steinboeck.   

Abstract

The parenteral application of the vasoactive drug, iloprost, might be a viable option for the treatment of BMES of different origins, especially ischemic ones. In edema that is secondary to osteoarthrosis or stress, the effect of therapy with iloprost depends on the grade of the basic disease. The natural course of the disease, as well as the normalization of the signal pattern of the MRI, seem to be accelerated.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14719835     DOI: 10.1016/s1083-7515(03)00145-1

Source DB:  PubMed          Journal:  Foot Ankle Clin        ISSN: 1083-7515            Impact factor:   1.653


  10 in total

Review 1.  [Pharmacotherapeutic aspects of femoral head necrosis].

Authors:  I H Tarner; R Dinser; U Müller-Ladner
Journal:  Orthopade       Date:  2007-05       Impact factor: 1.087

2.  Transient osteoporosis of the hip: successful treatment with teriparatide.

Authors:  Gianluigi Fabbriciani; Matteo Pirro; Maria Rosaria Manfredelli; Massimo Bianchi; Silvio Sivolella; Anna Maria Scarponi; Elmo Mannarino
Journal:  Rheumatol Int       Date:  2010-03-18       Impact factor: 2.631

3.  Efficiency of iloprost treatment for osseous malperfusion.

Authors:  Marcus Jäger; Christoph Zilkens; Bernd Bittersohl; Travis Matheney; Gordana Kozina; Dirk Blondin; Rüdiger Krauspe
Journal:  Int Orthop       Date:  2010-03-21       Impact factor: 3.075

4.  Bone marrow oedema syndrome of the foot and ankle in a paediatric population: a retrospective case series with serial MRI evaluation.

Authors:  Hannah De Houwer; Nathalie Van Beek; Sandra Prinsen; Anne Van Riet; Jeoffrey De Roeck; Stefaan Verfaillie
Journal:  J Child Orthop       Date:  2020-10-01       Impact factor: 1.548

5.  Effects of intravenous iloprost therapy in patients with bone marrow oedema of the foot and ankle.

Authors:  Eric Röhner; Timo Zippelius; David Steindl; Jasmin Fussi; Carsten Perka
Journal:  Eur J Orthop Surg Traumatol       Date:  2013-09-19

Review 6.  [Pain management in non-juvenile, aseptic osteonecrosis].

Authors:  M Jäger; A Werner; S Lentrodt; U Mödder; R Krauspe
Journal:  Schmerz       Date:  2004-12       Impact factor: 1.107

Review 7.  [Conservative treatment of aseptic necrosis of the femoral head. Are there evidence-based therapy concepts?].

Authors:  C Lüring; J Beckmann; P H Pennekamp; O Linhardt; J Grifka; M Tingart
Journal:  Orthopade       Date:  2007-05       Impact factor: 1.087

Review 8.  Regional migratory osteoporosis and transient osteoporosis of the hip: are they all the same?

Authors:  Metin Uzun; Egemen Ayhan; Burak Beksac; Ozgür Karaman
Journal:  Clin Rheumatol       Date:  2013-04-05       Impact factor: 2.980

9.  Rationale for prostaglandin I2 in bone marrow oedema--from theory to application.

Authors:  Marcus Jäger; Frank Peter Tillmann; Thomas S Thornhill; Marcus Mahmoudi; Dirk Blondin; Gerd Rüdiger Hetzel; Christoph Zilkens; Rüdiger Krauspe
Journal:  Arthritis Res Ther       Date:  2008-10-03       Impact factor: 5.156

10.  Transient Migratory Osteoporosis of the Hip and Talus: A Case Report.

Authors:  Raju Vaishya; Amit Kumar Agarwal; Vipul Vijay; Abhishek Vaish
Journal:  J Orthop Case Rep       Date:  2017 May-Jun
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.